Figure 3.

Dose-dependent effects of IFN-γ (A) and effects of pharmacological manipulations of cell signaling pathways (B) on sPLA₂-IIA protein release from Jurkat cells treated with 5-aza-dC. Concentrations of sPLA₂-IIA protein in cell incubates determined after a 72-hour exposure of cells to 10 µM 5-aza-dC and increasing concentrations of IFN-γ are shown in panel A. Effects of cell signaling activators and inhibitors on the levels of sPLA₂-IIA after a 72-hour incubation with 25 ng/ml IFN-γ and 10 µM 5-aza-dC are shown in panel B. Forskolin (10 µM), PMA (30 ng/ml), H-1152 (10 µM), PD98059 (PD98; 50 µM), indirubin (100 nM), SP-600125 (SP600; 5 µM), mithramycin A (Mithram; 250 nM), CAPE (25 µM), or Jak inhibitor I (Jak Inhib; 1 µM) were added simultaneously with IFN-γ and 5-aza-dC. The data shown are the means ± SDs of analysis in triplicate and are representative of three independent experiments.